STSA - Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
- Credit Suisse - 29 th Annual Healthcare Conference -
November 9 th -1 2 th
- Stifel 2020 Virtual Healthcare Conference -
November 1 6 th -1 8 th
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the following conferences in the month of November. Please see additional details below:
| Credit Suisse 29 th Annual Healthcare Conference |
| Dates: |
| Monday – Thursday, November 9 th -12 th 2020 |
| Format: |
| One-on-One meetings with Satsuma Management |
| Location: |
| Virtual Meetings |
| Stifel 2020 Virtual Healthcare Conference |
| Date: |
| Monday – Wednesday, November 16 th -18 th 2020 |
| Format: |
| One-on-One meetings with Satsuma Management |
| Location: |
| Virtual Meetings |
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com .
INVESTOR AND CORPORATE CONTACTS :
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com